

## SUBJECT INDEX TO VOLUME 8

### A

- Acetylcholinesterase inhibitors
  - CHF 2819, 53–69
  - galantamine, 159–176
- Adrenoceptor antagonists
  - RX 821002, 177–192
- Almotriptan, 217–234
  - ADME studies, 224
  - chemistry, 218
  - clinical pharmacokinetics, 227
  - clinical profile, 230–232
  - mechanism of action, 221–223
  - metabolism, 226
  - pharmacodynamic properties, 219–223
  - pharmacokinetics, 224
  - pharmacology, 219–224
  - safety pharmacology, 223–224
  - toxicology, 227–230

AMP 397A, 199

### Analgesics

- buprenorphine, 377–390
  - dihydroetorphine, 391–404
- Aniracetam, 70–89
- behavioral pharmacology, 71–78
  - clinical potential, 84–85
  - mechanisms of action, 79–84
  - pharmacokinetics, 78–79

### Antidepressants

- duloxetine, 361–376
- flibanserin, 117–142
- moclobemide, 283–308
- (+)-S32504, 195
- SSR125543, 194
- TC-107, 194

### Antiparkinsonian drugs

JP-1730, 198

### Antipsychotics,

- JL13, 195
- LY404187, 255–282
- PNU-170413, 195
- SB-258741, 90–100

Atipamezole, 197

### B

- BMS-204352, 353–360
  - chemistry, 355–356
  - clinical development, 358–359
  - pharmacology, 356–357
  - preclinical development, 358
- Buprenorphine, 377–390
  - clinical use, 382–384
  - pharmacokinetics, 381–382
  - pharmacology, 378–381

### C

- CEB-1604, 198–199
- Cognition enhancing drugs
  - aniracetam, 70–89
  - atipamezole, 197
  - CHF2819, 53–69, 200
  - ensaculin (KA-672), 143–158
  - FK-960, 197
  - galantamine, 159–176
  - pregnenolone sulfate, 197
  - S 17092, 31–52
  - (S)-3,5-DHPG, 101–116
  - tandospirone, 198
- CHF2819, 53–69
  - anticholinesterase activity, 56–57
  - behavioral pharmacology, 63–66
  - biochemical pharmacology, 57–63
  - neurotoxicity assessment, 66–67
- CX614, structure, 335

### D

- Dihydroetorphine, 391–404
  - adverse effects, 396–398
  - analgesic effect, 394
  - clinical studies, 399–400
  - dependence, 396–397
  - discovery, 392–393
  - formulation, 400–401
  - pharmacokinetics, 398–399
  - pharmacology, 392–396
  - rewarding properties, 397
  - selectivity for opioid receptors, 393–394
  - tolerance to analgesia, 394–395
- Duloxetine, 361–376
  - clinical studies in depression, 371–372
  - behavioral effects, 371
  - binding profile, 364–365
  - effects in models of aging, 370–371
  - electrophysiology, 367–368
  - inhibition of NE and 5-HT uptake, 365–367
  - other clinical uses, 372–373

### E

- Enoxaparin, 1–30
  - activity in stroke models, 11–17
  - traumatic brain injury, 17–19
  - brain lesion models, 19–22
- Ensaculin, 143–158
  - chemistry, 145
  - clinical studies, 155–156
  - pharmacokinetics, 153–155
  - pharmacology, 145–153
  - toxicology, 153

**F**

- FK 960, 197
- Flibanserin, 117–142
  - behavioral effects, 131–138
  - electrophysiology, 124–127
  - 5-HT turnover, effect on, 127–129
  - receptors, activity at, 118–124

**G**

- Galantamine, 159–176, 504–426
  - activity in animal models, 413–416
  - activity in brain slices, 412–413
  - chemistry, 161
  - clinical studies in Alzheimer's patients, 166–172
  - history, 409
  - inhibition of acetylcholinesterase by, 409–410
  - nicotinic receptors, potentiation by, 410–412
  - pharmacokinetics, 164–172
  - pharmacology, 161–164
  - relevance to neuropathology of Alzheimer's disease, 416–420
- GYKI 52466, structure, 335
- GYKI 53784 (LY303070), 235–254
  - AMPA receptor modulators, interaction with, 240–242
  - AMPA receptor subunits, action on, 240
  - chemistry, 237–238
  - clinical applications, 248–250
  - excitatory neurotransmitters in auditory system, effects on, 244–246
  - interaction with kainate and pentobarbital, 243–244
  - neuroprotective effects, 246–248
  - pharmacology, 238–248
  - synaptic responses, effect on, 242–243

**J**

- JL13, 195
- JP-1730, 198
- JTC-801, 194

**K**

- KA-672 (ensaculin), 143–158

**L**

- LY303070 (see GYKI 53784), 235–254
- LY374973, structure, 333
- LY404187, 255–282
  - AMPA receptors, molecular biology, 257–259
    - pharmacology, 259–273
    - therapeutic potential of modulation, 273–278
  - AMPA receptor-dependent responses, potentiation of, 271–273
  - chemistry, 257
  - excitatory synaptic responses, potentiation of, 268–269
  - recruitment of, 269–271
- LY411575, structure, 333

**M**

- MDL28,170, structure, 206
- Meeting reports
  - Neurobiology and Neuropharmacology of Alzheimer's Disease, 331–336
  - Neuroplasticity, 14th annual symposium, 207–216
  - Neuroscience, 2001, 193–200
  - Neurotrauma, 2001, 201–206
  - XIVth World Congress of Pharmacology, New CNS drugs, 427–437
- Moclobemide, 283–308
  - absorption and distribution, 248–249
  - animal models of depression, effects in, 295
  - antinociceptive activity, 296
  - anxiolytic activity, 295–296
  - chemistry, 286
  - cognition, effects on, 296–297
  - evolution of, 284–285
  - MAO inhibition by, 287–289
  - metabolism and elimination, 299–300
  - neuroendocrine effects, 293–294
  - neuroprotective effect, 297
  - pharmacokinetics, 297–299
  - sleep, effects on, 296
  - tyramine, interaction with, 294–295

**N**

- Neuroprotective drugs
  - AMP 397A, 199
  - arxoxifene, 321–322
  - CB-1604, 198–199
  - enoxaparin, 1–30
  - ensaculin, 143–158
  - GYKI 53784, 235–254
  - raloxifene, 316–321
  - YM 872, 337–352
- Nicotinic cholinergic modulation, 405–426
- NS2710, 196

**P**

- PNU-170413, 195
- Potassium channel openers
  - BMS-204352, 337–344
- Pregnenolone sulfate, 197

**Q**

- Quercetin, 205

**R**

- RX 821002, 177–192
  - chemical structure, 179
  - pharmacokinetics, 179–180
  - pharmacology, 179–188
  - receptors, interaction with, 180–184

**S**

- S 17092, 31–52
  - animal pharmacokinetics, 33–34
  - chemistry, 33
  - cognition activating activity, 37–45

- human pharmacodynamics, 45–50
  - human pharmacokinetics, 45–50
  - interaction with substance P, 36–37
  - mechanism of action, 34–36
  - S32504, 195
  - (S)-3,5-DHPG, 101–116
    - behavioral effects, 110–112
    - chemistry, 102–103
    - electrophysiology, 106–107
    - pharmacology, 108–110
    - receptors, interaction with, 103–104
    - second messengers, interaction with, 104–105
    - transmitter release, effect on, 105–106
  - SB-258741, 90–100
    - chemistry, 91–92
    - clinical potential, 96–97
    - pharmacology, 92–96
    - safety pharmacology, 96
  - SERMs (selective estrogen receptor modulators), 309–330
    - arzoxifene (LY355381), 321–322
    - future directions in development of, 323–324
    - mechanism of action, 311–313
    - profiles in the brain, 316–322
    - raloxifene, 316–322
      - brain penetration, 317
      - cognition, effect on, 319–320
      - hypothalamic pituitary gonadal axis, effect on, 318–319
      - nerve growth factor effect on, 320
      - neuroprotective effects, 320–321
      - neurotransmitter receptors, effects on, 317–318
      - tissue actions, 313–315
  - Spiradoline, 196
  - SSR125543, 154
- T**
- Tandospirone, 198
  - TC-1707, 194
  - Taurodiline, 205
- Y**
- YM872, 337–352
    - affinity for amino acid receptors, 339
    - affinity for glutamate receptors, 339
    - characterization, *in vitro*, 339–341
    - chemistry, 338–339
    - clinical trials, 350
    - inhibition of AMPA-induced Ca<sup>2+</sup> entry, 340
    - inhibition of kainate-induced inward current in oocytes, 339–340
    - inhibition of kainate-induced neurotoxicity, 340–341
    - mechanism of action, 349–350
    - neuroprotective profile, *in vivo*, 341–349